A new StockWatch market wrap described a comeback year for biotech, pointing to gains in major biotech ETFs and a surge in IPO activity in 2026 compared with 2025 levels. The update cites market performance, including momentum in both initial public offerings and ongoing capital markets activity. The article also reported shifting deal dynamics: global licensing fell to a two-year low in Q3 value and transaction count, while deal average size declined as transactions skewed toward later clinical-stage assets. In contrast, M&A value remained elevated over the year-to-date period, and PIPE activity increased, reflecting continued appetite for public-company support. For biotech executives and strategy teams, the takeaway is the sector’s improved liquidity alongside tighter licensing economics and more selective transaction structures—signals that can affect partnering targets, trial timelines, and fundraising strategies for clinical-stage and “NewCo” formation efforts.